Focused on the ophthalmology specialty field, sourcing and developing globally innovative products that address urgent clinical needs, and building a medical-grade eye health ecosystem

A large number of patients suffer from eye diseases in China. With population growth and aging, the burden of eye diseases is increasing significantly. Based on professional ophthalmic product portfolio, extensive expert and channel resources, CMS’ ophthalmology business (“CMS Vision”) focuses on identification, development and commercialization of urgent needed ophthalmic diagnosis and treatment, to accelerate development of innovative technologies in the ophthalmology field.

Ophthalmology Line

Augentropfen Stulln Mono Eye Drops (Esculin and Digitalisglycosides Eye Drops) (exclusive product)

Indication
Senile macular degeneration and all forms of asthenopia

EyeOP1 Glaucoma Treatment Device (exclusive product)

Indication
Glaucoma with intraocular pressure that cannot be controlled by drugs and surgery

 

BEOVU (Brolucizumab Injection) (innovative drug)

Indication
Diabetic macular edema

LUCENTIS (Ranibizumab Injection)

Indication
- Neovascular age related macular degeneration
- Diabetic macular edema
- Macular edema following retinal vein occlusion
- Choroidal neovascularization
- Diabetic retinopathy
- Retinopathy of prematurity

The information on this page is only for the introduction of the medicines and medical devices to partners or medical professionals, not for product advertising. The product information on this website shall not replace medical advice and medical consultation provided by doctors or other qualified medical professionals, and shall not be used for disease diagnosis. For detailed information about the medicines and medical devices, please refer to the latest product instructions. If you have understood and confirmed the above content, please click OK to enter.